Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis

Maiga, Fatoumata O.; Wele, Mamadou; Toure, Sounkou M.; Keita, Makan; Tangara, Cheick Oumar; Refeld, Randi R.; Thiero, Oumar; Kayentao, Kassoum; Diakite, Mahamadou; Dara, Antoine; Li, Jian; Toure, Mahamoudou; Sagara, Issaka; Djimdé, Abdoulaye; Mather, Frances J.; Doumbia, Seydou O.; Shaffer, Jeffrey G.

doi:10.1186/s12936-021-03890-0

Table 1 Characteristics of selected artemisinin-based combination therapy trials in Mali

From: Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis

No	Author, month, year, ref	Mali Study site	Lat °N	Lon °W	Study characteristics^b	Drug type	N	n	ACPR (%)	ACPRc (%)
1	Sagara Oct 2006 [47]	Sotuba	12.66	7.91	≥ 6 months; Sep 2003–Jan 2004	AL	303	297	89.6	99.0
1	Sagara Oct 2006 [47]	Sotuba	12.66	7.91	≥ 6 months; Sep 2003–Jan 2004	AS + SMP	303	296	98.7	100.0
2	Djimde Mar 2008 [48]	Bougoula-Hameau	10.78	6.92	≥ 5 kg; Dec 2002–Oct. 2004	AS + AQ	252	235	81.3	99.1
						AS + SP	250	232	95.7	100.0
						AS	251	234	57.7	96.5
3	Sagara Nov 2008 [49]	Kambila	12.79	8.11	≥ 10 kg, ≥ 1 yr; Aug 2004–Feb 2005	AL	235	232	67.8	96.9
3	Sagara Nov 2008 [49]	Kambila	12.79	8.11	≥ 10 kg, ≥ 1 yr; Aug 2004–Feb 2005	AS + MQ	235	232	79.7	96.0
4	Kayentao Jan 2009 [57]	Faladje	13.13	8.33	6–59 months; July 2005–Jan 2006	AS + AQ	133	131	55.7	95.4
						AS + SP	132	130	90.8	96.9
						SP + AQ	132	130	97.7	99.2
5	Sagara Apr 2009 [50]	Bancoumana	12.21	8.26	≥ 6 months; Aug 2006–May 2007	AL	253	85	NR	100.0
		Kolle	12.23	8.24		AS + SMP, 1 day		82	NR	100.0
		Samako	12.26	8.28		AS + SMP, 3 days		86	NR	100.0
6^a	Ndiaye Jun 2009 [51]	Bancoumana	12.21	8.26	≥ 10 kg; Mar 2006–Dec 2006	AL	67	65	NR	94.0
						AS + AQ, 1 day	66	64	NR	93.9
						AS + AQ, 2 days	68	65	NR	95.6
7	Sagara Jul 2012 [52]	Bougoula-Hameau	10.78	6.92	≥ 6 months; July 2005–July 2007	AL	260	252	62.0	94.4
						AS + AQ	260	252	78.5	95.8
						AS + SP	260	253	89.1	97.9
8	Kayentao Oct 2012 [58]	Bougoula	11.15	7.49	≥ 5 to < 25 kg, ≤ 12 yrs; Nov 2007–Sep 2008	AL	NR	43	NR	100.0
8	Kayentao Oct 2012 [58]	Bougoula	11.15	7.49	≥ 5 to < 25 kg, ≤ 12 yrs; Nov 2007–Sep 2008	AS + Pyr	NR	84	NR	100.0
9	Maiga Feb 2015 [59]	Kolle	12.23	8.24	6–59 months; Dec 2004–Dec 2005	AS + SP	306	296	94.9	99.0
		Bancoumana	12.21	8.26		SP + AQ	304	293	98.6	100.0
		Bancoumana	12.21	8.26		SP	302	294	93.5	97.2
10	Niaré Mar 2016 [54]	Banambani	12.79	8.04	≥ 6 months; Oct 2010–Jan 2014	AL	237	228	83.8	98.2
		Sotuba	12.66	7.91		AS + SP	242	228	91.2	100.0
		Kolle	12.23	8.24		AS + SP	242	228	91.2	100.0
11	Dama Oct 2018 [56]	Doneguebougou	12.81	7.98	≥ 6 months; Nov 2013–Dec 2015	AL	158	155	84.5	98.1
11	Dama Oct 2018 [56]	Torodo	13.06	8.21	≥ 6 months; Nov 2013–Dec 2015	DHA + PQ	159	155	97.4	99.4

Column 1 is a sequential number according to the ascending order of month and year of publication. Column 2 shows the last name of the first author and month and year of publication for each study, respectively. Columns 4 and 5 include GPS coordinates (latitude and longitude, respectively). Age and weight range inclusion criteria and study time period are shown in Column 6. Treatment arm, number of subjects enrolled per study arm, and number of subjects evaluated (number of enrolled subjects excluding withdrawals) by study arm are shown in Columns 7, 8 and 9, respectively. ACPRs and ACPRcs (as percentages of non-treatment failures) are listed in Columns 10 and 11. All 11 studies employed supervised drug administration
All results based on per protocol analyses, save for study number 6 (Ndiaye et al. [51]) as country-specific results were only available for intention-to-treat analyses
ACT: artemisinin-based combination therapy; lat.: latitude; lon.: longitude; ACPR: adequate clinical and parasite response at 28 days; ACPRc: polymerase chain reaction-corrected adequate clinical and parasite response at 28 days; CI: confidence interval; NR: Not reported; PCR: polymerase chain reaction; +: joint combination of treatment regimens; Drug types: AL: artemether–lumefantrine; AP: artesunate–pyronaridine; AQ: amodiaquine; AS: artesunate; AS + MQ: artesunate–mefloquine; CD: chlorproguanil–dapsone; DHA: dihydroartemisinin; PQ: piperaquine; Pyr: pyronaridine; SMP: sulfamethoxypyrazine–pyrimethamine; SP: sulfadoxine–pyrimethamine
^a Results based on intention-to-treat analyses
^b Study characteristics include and weight inclusion criteria and study time period for those studies where this information was available

Back to article page

ISSN: 1475-2875

Contact us

Submission enquiries: journalsubmissions@springernature.com

Malaria Journal

Contact us